Strong Financial Performance: Boston Scientific reported a 21.4% organic sales growth and raised its 2025 revenue and earnings outlook, indicating a positive financial trajectory.
Strategic Partnership: The company entered an exclusive distribution agreement with Siemens Healthineers for the AcuNav 4D ICE catheter, aimed at enhancing the adoption of its Watchman platform, a key revenue growth driver.
Investment Considerations: Investors are encouraged to weigh Boston Scientific's growth potential against challenges such as margin pressure from tariffs and reimbursement changes, as well as the need for ongoing innovation.
Future Projections: Boston Scientific aims for $25.4 billion in revenue and $4.8 billion in earnings by 2028, requiring consistent growth, with fair value estimates for the stock ranging from $67.22 to $126.48 per share.
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 91.290
Low
112.00
Averages
125.74
High
140.00
Current: 91.290
Low
112.00
Averages
125.74
High
140.00
Canaccord
Buy
to
Hold
downgrade
$359 -> $374
2026-01-20
New
Reason
Canaccord
Price Target
$359 -> $374
AI Analysis
2026-01-20
New
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $359. The firm cites Boston Scientific's (BSX) agreement to acquire Penumbra in a stock-and-cash transaction that values Penumbra at $374 per share for the downgrade. Canaccord does not expect any competitive bids for Penumbra.
RBC Capital
Outperform
to
Sector Perform
downgrade
$355 -> $374
2026-01-20
New
Reason
RBC Capital
Price Target
$355 -> $374
2026-01-20
New
downgrade
Outperform
to
Sector Perform
Reason
RBC Capital downgraded Penumbra (PEN) to Sector Perform from Outperform with a price target of $374, up from $355. The firm cites Boston Scientific's (BSX) agreement to acquire Penumbra in a stock-and-cash transaction that values Penumbra at $374 per share for the downgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BSX
Unlock Now
Jefferies
Buy
to
Hold
downgrade
$335 -> $374
2026-01-16
Reason
Jefferies
Price Target
$335 -> $374
2026-01-16
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $335, following the announcement of a deal to be acquired by Boston Scientific (BSX). The firm views the price as "healthy" and thinks the deal makes strategic sense, adding that it does not expect another bidder and does expect the deal to ultimately close, but after "some regulatory scrutiny."
Leerink
Mike Kratky
Outperform
to
Market Perform
downgrade
$374
2026-01-15
Reason
Leerink
Mike Kratky
Price Target
$374
2026-01-15
downgrade
Outperform
to
Market Perform
Reason
Leerink analyst Mike Kratky downgraded Penumbra (PEN) to Market Perform from Outperform with a $374 price target after Boston Scientific (BSX) entered an agreement to acquire Penumbra in a cash and stock transaction valued at $14.5B, or $374 per share.
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
